China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch of its AnchorMan left atrial appendage occluder system and guidance system in China, adding new revenue streams.
Product Launches and Revenue Drivers
The AnchorMan systems’ launch in China contributed to the revenue growth, alongside continued demand for VitaFlow Liberty and Alwide Plus. These products have been pivotal in expanding CardioFlow Medtech’s market presence both domestically and internationally.
TAVI Products’ Global Expansion
Transcatheter aortic valve implantation (TAVI) products made significant inroads globally, accessing over 80 new hospitals in China, bringing the domestic total to 630. The third-generation TAVI product, VitaFlow Liberty, achieved a milestone by becoming the first Chinese intelligent-manufacturing TAVI system with a CE mark in April 2024. By the end of the reporting period, CardioFlow Medtech’s TAVI products had entered nearly 100 hospitals across Argentina, Colombia, Thailand, Russia, Italy, Spain, Chile, Switzerland, and other countries.
Strategic Acquisition
During the period, CardioFlow Medtech acquired 51% stakes in Shanghai Zuoxin Medical Technology Co., Ltd, marking its entry into the high-growth niche market of stroke prevention in non-valvular atrial fibrillation patients within the structural heart disease sector.-Fineline Info & Tech
Leave a Reply